AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 55 filers reported holding AKERO THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $4,000 | -87.5% | 398 | -82.2% | 0.00% | -100.0% |
| Q1 2022 | $32,000 | +113.3% | 2,242 | +244.9% | 0.00% | – |
| Q3 2021 | $15,000 | -77.9% | 650 | -76.1% | 0.00% | -100.0% |
| Q2 2021 | $68,000 | +750.0% | 2,723 | +951.4% | 0.00% | – |
| Q1 2021 | $8,000 | -46.7% | 259 | -56.5% | 0.00% | -100.0% |
| Q4 2020 | $15,000 | -11.8% | 595 | +5.1% | 0.00% | -50.0% |
| Q3 2020 | $17,000 | +88.9% | 566 | +55.5% | 0.00% | +100.0% |
| Q2 2020 | $9,000 | +800.0% | 364 | +1113.3% | 0.00% | – |
| Q1 2020 | $1,000 | -85.7% | 30 | -91.0% | 0.00% | -100.0% |
| Q4 2019 | $7,000 | -90.9% | 332 | -91.7% | 0.00% | -90.5% |
| Q2 2019 | $77,000 | – | 4,008 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |